163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study

Chan, Anthony T.C.; Lee, H.F.V.; Hong, R-L.; Ahn, M-J.; Chong, Wan Qin; Kim, SB; Fuang, Ho Gwo; Caguioa, Priscilla B.; Ngamphaiboon, Nuttapong; Ho, Cheryl; Aziz, M.A.S. Abdul; Ng, Quan Sing; Yen, Chia‐Jui; Soparattanapaisarn, Nopadol; Ngan, Roger K.C.; Kho, S.K.; Wang, L.; Swaby, Ramona F.; Saraf, Sanatan; Siu, Lillian L.

doi:10.1016/j.annonc.2021.10.182

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[25][26][27] The relative stability of HRQoL observed in the current study is similar to the findings reported in KEYNOTE-122 which found that scores on the EQ-5D-3 L 34 visual analog scale were stable through week 18 in patients with nasopharyngeal cancer receiving pembrolizumab compared with a group receiving capecitabine, gemcitabine, or docetaxel. 12 HRQoL stability in the QLQ-C30 or QLQ-H&N35 questionnaires through 15 weeks of therapy has also been reported in CheckMate 141 for patients with recurrent or metastatic squamous head and neck cancer. 35 In the current study, a reduction in pain at cycle 8 was observed in patients treated with tislelizumab + chemotherapy compared with patients treated with placebo + chemotherapy in both the ITT population and the liver metastases subgroup.…”

Section: Discussionmentioning

confidence: 84%

“…10 Some studies have suggested that these agents may also stabilize and slightly improve HRQoL while they reduce some symptoms. 11,12 However, other studies have reported mixed results. 13,14 Aside from inconsistent findings regarding effects of immunotherapeutic agents on HRQoL for patients with nasopharyngeal cancer, it is unclear whether these agents also have any impact on the HRQoL of patients with nasopharyngeal cancer and liver metastases due to the lack of data.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Effects of tislelizumab on health‐related quality of life in patients with recurrent or metastatic nasopharyngeal cancer

Yang,

Pan,

Chen

et al. 2024

Head & Neck

View full text Add to dashboard Cite

BackgroundThis study evaluated health‐related quality of life (HRQoL) in the RATIONALE‐309 (NCT03924986) intent‐to‐treat (ITT) population and in a subgroup of patients with liver metastases.MethodsPatients were randomized 1:1 to tislelizumab + chemotherapy or placebo + chemotherapy. As the secondary endpoint, HRQoL was evaluated using seven selected scores from the EORTC QLQ‐C30 and QLQ Head and Neck Cancer module (QLQ‐H&N35).ResultsOf 263 randomized patients in the ITT population (tislelizumab + chemotherapy n = 131, placebo + chemotherapy n = 132), 43% had liver metastases (tislelizumab + chemotherapy n = 56; placebo + chemotherapy n = 57). No differences in change in selected scores on the QLQ‐C30 from baseline to cycle 4 or cycle 8 were observed for the ITT or liver metastases subgroup. No differences in selected QLQ‐H&N35 scores were observed between the arms from baseline to cycle 4. In the ITT population and the liver metastases subgroup, a greater reduction from baseline to cycle 8 was observed in the tislelizumab + chemotherapy arm than the placebo + chemotherapy arm in QLQ‐H&N35 pain score. At cycle 8 in the liver metastases subgroup, the tislelizumab + chemotherapy arm experienced greater improvement in the QLQ‐H&N35 senses problems score than the placebo + chemotherapy arm. Differences in time to deterioration between arms were not observed.ConclusionsThe current findings, along with improved survival and favorable safety, suggests that tislelizumab + chemotherapy represents a potential first‐line treatment for recurrent or metastatic nasopharyngeal cancer.

show abstract